Hidden BRD4-S Protein Shields Gastric Tumors From Cell Death and Blunts Chemotherapy

Gastric cancer remains one of the world’s most lethal malignancies, and one of its most frustrating features is how unevenly patients respond to chemotherapy. A drug that shrinks one tumor completely may leave another virtually untouched, and oncologists have long lacked reliable molecular explanations for that difference. A new study published in the Journal of Experimental & Clinical Cancer Research by Yize Liang, Wenbin Yu, Xiaohan Cui and colleagues at Qilu Hospital of Shandong University, working with collaborators at the University of Texas Southwestern Medical Center, now offers a striking candidate: a little-studied short form of a gene-regulating protein called BRD4 appears to act as a metabolic bodyguard for gastric tumor cells, protecting them from a form of cell death called ferroptosis and, in doing so, quietly undermining one of the most widely used chemotherapy drugs in stomach cancer treatment.

BRD4, or bromodomain-containing protein 4, is a transcriptional co-regulator that has attracted intense interest in cancer research because it helps orchestrate which genes are switched on and how actively they are read. What makes the new work distinctive is its focus on isoforms, the different protein variants produced from the same gene. The BRD4 gene can generate at least two major products, a long form known as BRD4-L and a short form known as BRD4-S. These variants are not interchangeable duplicates. The research team set out to determine whether they play distinct roles in gastric cancer biology, and their answer was unambiguous: only the short form, BRD4-S, behaved as a driver of aggressive disease.

Using isoform-specific genetic manipulation in gastric cancer cell lines, the investigators showed that BRD4-S, but not BRD4-L, promoted cell proliferation and invasion. When the team examined tumor samples from patients, high BRD4-S expression tracked with unfavorable clinical outcomes, marking it as a potential biomarker of poor prognosis. That observation alone would have been noteworthy, but the real surprise came when the researchers asked what happens to gastric cancer cells when BRD4-S is removed. The cells did not simply slow down. They became dramatically more vulnerable to ferroptosis, an iron-dependent form of regulated cell death driven by the accumulation of lipid peroxides in cellular membranes.

Ferroptosis has emerged over the past decade as a promising therapeutic angle in oncology because many cancer cells, by virtue of their altered metabolism, sit close to the threshold of this oxidative form of death. The cell’s main defense against it is glutathione, a small tripeptide antioxidant that the enzyme glutathione peroxidase 4 uses to neutralize lipid peroxides. Deplete glutathione and the membranes begin to oxidize uncontrollably. When Liang and colleagues depleted BRD4-S in gastric cancer cells, they observed precisely this cascade: intracellular glutathione levels fell, lipid peroxidation rose, and the cells succumbed far more readily to ferroptotic triggers.

The mechanistic heart of the paper lies in how BRD4-S maintains the glutathione supply line. Through co-immunoprecipitation experiments, the team found that BRD4-S physically interacts with YY1, a well-known transcription factor, and that this partnership facilitates YY1’s occupancy at the promoters of two genes: PCK2, which encodes phosphoenolpyruvate carboxykinase 2, and SLC7A11, which encodes the light chain of the cystine-glutamate antiporter that imports cystine, the raw material for glutathione synthesis. Chromatin immunoprecipitation confirmed that BRD4-S loss reduced YY1 binding at these regulatory regions, and with it, expression of both genes.

Each of those two genes contributes a distinct piece of the antioxidant puzzle. SLC7A11 supports the uptake of cystine from the extracellular environment, providing the limiting building block for glutathione. PCK2, an enzyme better known for its role in gluconeogenesis within mitochondria, was shown here to steer glutamine metabolism toward glutathione production. The researchers demonstrated this using carbon-13 and nitrogen-15 labeled glutamine tracing, a technique that allows biochemists to follow the fate of individual atoms as they flow through metabolic networks. Together, PCK2 and SLC7A11 form a two-pronged program that keeps glutathione homeostasis intact and lipid peroxidation in check.

The functional importance of this program was confirmed by rescue experiments. When the team restored PCK2 and SLC7A11 expression in cells lacking BRD4-S, the ferroptotic phenotype partially reversed: glutathione recovered, lipid peroxidation subsided, and the cells regained their resistance. The same restoration blunted the increased sensitivity to oxaliplatin, a platinum-based chemotherapy drug commonly used in neoadjuvant regimens for gastric cancer. Critically, these rescue effects held not only in cultured cells but also in animal models, where re-expression of the two metabolic genes partially restored tumor growth and drug resistance in vivo.

The link to oxaliplatin is where the study acquires its most direct clinical relevance. Oxaliplatin’s cytotoxicity is intertwined with oxidative stress, and tumors with robust antioxidant capacity tend to withstand it better. Because BRD4-S sustains the glutathione buffer, high BRD4-S tumors are effectively pre-armored against the oxidative component of the drug’s action. The clinical data bore this out: among gastric cancer patients treated with oxaliplatin-based neoadjuvant chemotherapy, those with lower BRD4-S expression in their tumors showed a higher rate of major pathological response and reached a more favorable post-treatment pathological stage. In other words, BRD4-S levels in the pretreatment tumor appeared to predict how well the chemotherapy would work.

These findings carry several implications for the field. First, they underscore that BRD4 isoforms must be studied separately; lumping them together in pan-BRD4 assays or pan-BRD4 inhibitors may obscure the specific contribution of the short form. Second, they position ferroptosis sensitivity as a tunable property of gastric cancer cells, one that can be dialed down by a single transcriptional regulator acting through YY1. Third, they suggest a potential therapeutic window: combining oxaliplatin with strategies that suppress BRD4-S, disrupt its interaction with YY1, or otherwise deplete glutathione defenses could sensitize otherwise resistant tumors. The authors frame BRD4-S as a potential therapeutic vulnerability, and the rescue data provide a mechanistic rationale for that framing.

As with any laboratory and clinical-correlate study, important questions remain before this biology can be translated into the clinic. The work was conducted with cell lines, animal models, and patient cohorts from a single institution, and prospective validation in larger, independent patient populations will be needed to establish BRD4-S as a predictive biomarker for oxaliplatin response. Whether pharmacological tools can selectively target BRD4-S without disturbing the long isoform is another open challenge, since isoform-selective inhibition remains technically demanding. Nevertheless, the study adds a compelling new node to the growing map connecting epigenetic regulators, glutamine metabolism, and ferroptosis in cancer, and it offers gastric cancer patients and their physicians a measurable molecular feature that may help forecast who will benefit from one of the standard weapons against this disease.

Subject of Research: BRD4-S regulation of glutathione metabolism, ferroptosis resistance, and oxaliplatin response in gastric cancer

Article Title: BRD4-S reprograms glutathione metabolism to reduce ferroptosis sensitivity and limits oxaliplatin response in gastric cancer

Article References: Liang, Y., Wei, M., Yan, Z., Sun, G., Zhao, H., Sun, D., Yang, W., Cheng, Z., Wang, H., Wu, S.-Y., Chiang, C.-M., Cui, X., & Yu, W. (2026). BRD4-S reprograms glutathione metabolism to reduce ferroptosis sensitivity and limits oxaliplatin response in gastric cancer. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-026-03855-8

Image Credits: AI Generated

DOI: 10.1186/s13046-026-03855-8

Keywords: gastric cancer, BRD4-S, ferroptosis, glutathione, PCK2, SLC7A11, YY1, oxaliplatin, cancer metabolism, chemotherapy response, lipid peroxidation, transcriptional regulation